Larimar Therapeutics (LRMR) Debt to Equity: 2014-2020
Historic Debt to Equity for Larimar Therapeutics (LRMR) over the last 5 years, with Mar 2020 value amounting to $0.13.
- Larimar Therapeutics' Debt to Equity fell 19.03% to $0.13 in Q1 2020 from the same period last year, while for Mar 2020 it was $0.13, marking a year-over-year decrease of 19.03%. This contributed to the annual value of -$12.20 for FY2019, which is 7591.14% down from last year.
- As of Q1 2020, Larimar Therapeutics' Debt to Equity stood at $0.13, which was up 101.09% from -$12.20 recorded in Q4 2019.
- In the past 5 years, Larimar Therapeutics' Debt to Equity ranged from a high of $0.36 in Q2 2018 and a low of -$12.20 during Q4 2019.
- Over the past 3 years, Larimar Therapeutics' median Debt to Equity value was $0.16 (recorded in 2019), while the average stood at -$1.17.
- Over the last 5 years, Larimar Therapeutics' Debt to Equity had its largest YoY gain of 4.76% in 2019, and its largest YoY loss of 7,591.14% in 2019.
- Over the past 5 years, Larimar Therapeutics' Debt to Equity (Quarterly) stood at $0.01 in 2016, then reached $0.26 in 2017, then tumbled by 36.33% to $0.16 in 2018, then crashed by 7,591.14% to -$12.20 in 2019, then fell by 19.03% to $0.13 in 2020.
- Its Debt to Equity stands at $0.13 for Q1 2020, versus -$12.20 for Q4 2019 and $0.17 for Q3 2019.